Ceftolozane-tazobactam activity against phylogenetically diverse clostridium difficile strains

Mark D. Gonzalez; Meghan A. Wallace; Tiffany Hink; Erik R. Dubberke; Carey Ann D. Burnham

doi:10.1128/AAC.01670-15

Ceftolozane-tazobactam activity against phylogenetically diverse clostridium difficile strains

Mark D. Gonzalez, Meghan A. Wallace, Tiffany Hink, Erik R. Dubberke, Carey Ann D. Burnham

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Ceftolozane-tazobactam (C/T) is approved for the treatment of complicated intra-abdominal and urinary tract infections and has varied activity against anaerobic bacteria. Here, we evaluate the activity of C/T against a phylogenetically diverse collection of Clostridium difficile isolates and report uniformly high MICs (≥256 μg/ml) to C/T.

Original language	English
Pages (from-to)	7084-7085
Number of pages	2
Journal	Antimicrobial agents and chemotherapy
Volume	59
Issue number	11
DOIs	https://doi.org/10.1128/AAC.01670-15
State	Published - Nov 1 2015

Access to Document

10.1128/AAC.01670-15

Cite this

@article{c2a4078c53834bc6a3651e07f2fcee72,

title = "Ceftolozane-tazobactam activity against phylogenetically diverse clostridium difficile strains",

abstract = "Ceftolozane-tazobactam (C/T) is approved for the treatment of complicated intra-abdominal and urinary tract infections and has varied activity against anaerobic bacteria. Here, we evaluate the activity of C/T against a phylogenetically diverse collection of Clostridium difficile isolates and report uniformly high MICs (≥256 μg/ml) to C/T.",

author = "Gonzalez, {Mark D.} and Wallace, {Meghan A.} and Tiffany Hink and Dubberke, {Erik R.} and Burnham, {Carey Ann D.}",

year = "2015",

month = nov,

day = "1",

doi = "10.1128/AAC.01670-15",

language = "English",

volume = "59",

pages = "7084--7085",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

number = "11",

}

TY - JOUR

T1 - Ceftolozane-tazobactam activity against phylogenetically diverse clostridium difficile strains

AU - Gonzalez, Mark D.

AU - Wallace, Meghan A.

AU - Hink, Tiffany

AU - Dubberke, Erik R.

AU - Burnham, Carey Ann D.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Ceftolozane-tazobactam (C/T) is approved for the treatment of complicated intra-abdominal and urinary tract infections and has varied activity against anaerobic bacteria. Here, we evaluate the activity of C/T against a phylogenetically diverse collection of Clostridium difficile isolates and report uniformly high MICs (≥256 μg/ml) to C/T.

AB - Ceftolozane-tazobactam (C/T) is approved for the treatment of complicated intra-abdominal and urinary tract infections and has varied activity against anaerobic bacteria. Here, we evaluate the activity of C/T against a phylogenetically diverse collection of Clostridium difficile isolates and report uniformly high MICs (≥256 μg/ml) to C/T.

UR - http://www.scopus.com/inward/record.url?scp=84946234354&partnerID=8YFLogxK

U2 - 10.1128/AAC.01670-15

DO - 10.1128/AAC.01670-15

M3 - Article

C2 - 26282409

AN - SCOPUS:84946234354

VL - 59

SP - 7084

EP - 7085

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

ER -

Ceftolozane-tazobactam activity against phylogenetically diverse clostridium difficile strains

Abstract

Access to Document

Other files and links

Fingerprint

Cite this